The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...
Hosted on MSN2mon
Could a pill replace gene therapy for sickle cell disease? Research uncovers potential path to small-molecule drug"The editing therapy is a wonderful achievement ... It does so by suppressing the gene BCL11A, which normally shuts down fetal hemoglobin production after birth. This lets fetal hemoglobin ...
Hosted on MSN27d
MaxCyte: Building the Future of Cell and Gene Therapy InnovationMaxCyte's technology ensures that a large number of T cells are successfully edited with CRISPR/Cas-9 molecular scissors, which is critical for the effectiveness of the therapy. Casgevy enables CRISPR ...
The therapy, known as CTX001, is applied to blood stem cells removed from the patient to cleave the BCL11A gene that represses the production of fetal hemoglobin. These cells are then reinfused to ...
which is critical for the effectiveness of the therapy. Casgevy enables CRISPR/Cas-9 to edit the BCL11A gene in stem cells to produce fetal hemoglobin. The edited genes are infused into a patient ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback